# Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.

Study · id `cardio:ct-nct04521699` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04521699](<https://clinicaltrials.gov/study/NCT04521699>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04521699

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

## Technical summary

Registry record NCT04521699. Randomized; no masking; primary purpose treatment. Start 2022-01-13 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT04521699, source copy `cardio:ctgov-nct04521699-2026-05-05`, retrieved 2026-10-26)
- Started: 2022-01-13 (actual) (ClinicalTrials.gov record NCT04521699, source copy `cardio:ctgov-nct04521699-2026-05-05`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT04521699, source copy `cardio:ctgov-nct04521699-2026-05-05`, retrieved 2026-10-26)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT04521699, source copy `cardio:ctgov-nct04521699-2026-05-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04521699, source copy `cardio:ctgov-nct04521699-2026-05-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04521699-2026-05-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.
- Acronym: CalmiGo
- Condition: Myocardial Infarction
- Intervention (Device): CalmioGO Stress management device
- Lead sponsor: Mayo Clinic
- Lead sponsor class: OTHER
- Collaborator: CalmiGO
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Mayo Clinic (`cardio:org-mayo-clinic`)

## Provenance

Content hash: 9e5cdeaf8be8007d27472edcc5fe2643e18052239e85013036f1216a5ffee3fe
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
